• Je něco špatně v tomto záznamu ?

Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing

L. Kodjikian, L. Arias Barquet, A. Papp, PJ. Kertes, E. Midena, J. Ernest, R. Silva, T. Schmelter, T. Niesen, S. Leal

. 2024 ; 41 (3) : 1010-1024. [pub] 20240106

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, hodnocení ekvivalence, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006928

INTRODUCTION: AZURE was a 76-week, randomized, open-label, parallel-group, phase IIIb noninferiority study comparing the efficacy and safety of intravitreal aflibercept (IVT-AFL) in a treat-and-extend (T&E) regimen with fixed dosing in patients with neovascular age-related macular degeneration (nAMD) previously receiving IVT-AFL for ≥ 1 year. METHODS: Patients were aged ≥ 51 years and had completed ≥ 1 year of IVT-AFL treatment prior to enrollment (IVT-AFL once per month [- 1 or + 2 weeks] for 3 months followed by IVT-AFL every 2 months [6-12 weeks]). Patients were randomly assigned (1:1) to receive IVT-AFL 2 mg in either a T&E (minimum treatment interval of 8 weeks with no upper limit, adjusted according to functional and anatomic outcomes, as assessed by the investigator; n = 168), or a fixed dosing regimen (treatment every 8 weeks [± 3 days]; n = 168). The primary endpoint was best-corrected visual acuity (BCVA) change from baseline to week (W) 52. The key secondary endpoint was the proportion of patients maintaining vision (< 15-letter loss) at W52. RESULTS: The full analysis set comprised 332 patients (T&E: n = 165; fixed dosing: n = 167). Mean BCVA change (baseline to W52) was - 0.3 ± 7.5 vs. - 0.5 ± 8.4 letters (T&E vs. fixed dosing; least-squares mean difference [95% CI]: 0.22 [- 1.51 to 1.96] letters; P < 0.0001 for noninferiority test [5-letter margin]). From baseline to W52, 95.2% (T&E) and 94.0% (fixed dosing) of patients maintained vision. Mean central subfield thickness change from baseline to W52 was - 24 ± 55 (T&E) and - 33 ± 47 (fixed dosing) μm. Last treatment interval to W76 was ≥ 12 weeks for 37.0% of T&E patients. No new safety signals were identified. CONCLUSION: IVT-AFL T&E can achieve similar functional and anatomic outcomes to fixed dosing every 8 weeks over 52 weeks in patients with nAMD who have completed ≥ 1 year of treatment, while reducing treatment burden. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02540954.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006928
003      
CZ-PrNML
005      
20240423155601.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12325-023-02719-3 $2 doi
035    __
$a (PubMed)38183525
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kodjikian, Laurent $u Department of Ophthalmology, Croix-Rousse Teaching Hospital, Hospices Civils de Lyon, Lyon, France. laurent.kodjikian@chu-lyon.fr $u UMR-CNRS 5510 Matéis, Villeurbanne, Université Claude Bernard Lyon 1, University of Lyon, Lyon, France. laurent.kodjikian@chu-lyon.fr $1 https://orcid.org/0000000239086716
245    10
$a Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration Beyond One Year of Treatment: AZURE, a Randomized Trial of Treat-and-Extend vs. Fixed Dosing / $c L. Kodjikian, L. Arias Barquet, A. Papp, PJ. Kertes, E. Midena, J. Ernest, R. Silva, T. Schmelter, T. Niesen, S. Leal
520    9_
$a INTRODUCTION: AZURE was a 76-week, randomized, open-label, parallel-group, phase IIIb noninferiority study comparing the efficacy and safety of intravitreal aflibercept (IVT-AFL) in a treat-and-extend (T&E) regimen with fixed dosing in patients with neovascular age-related macular degeneration (nAMD) previously receiving IVT-AFL for ≥ 1 year. METHODS: Patients were aged ≥ 51 years and had completed ≥ 1 year of IVT-AFL treatment prior to enrollment (IVT-AFL once per month [- 1 or + 2 weeks] for 3 months followed by IVT-AFL every 2 months [6-12 weeks]). Patients were randomly assigned (1:1) to receive IVT-AFL 2 mg in either a T&E (minimum treatment interval of 8 weeks with no upper limit, adjusted according to functional and anatomic outcomes, as assessed by the investigator; n = 168), or a fixed dosing regimen (treatment every 8 weeks [± 3 days]; n = 168). The primary endpoint was best-corrected visual acuity (BCVA) change from baseline to week (W) 52. The key secondary endpoint was the proportion of patients maintaining vision (< 15-letter loss) at W52. RESULTS: The full analysis set comprised 332 patients (T&E: n = 165; fixed dosing: n = 167). Mean BCVA change (baseline to W52) was - 0.3 ± 7.5 vs. - 0.5 ± 8.4 letters (T&E vs. fixed dosing; least-squares mean difference [95% CI]: 0.22 [- 1.51 to 1.96] letters; P < 0.0001 for noninferiority test [5-letter margin]). From baseline to W52, 95.2% (T&E) and 94.0% (fixed dosing) of patients maintained vision. Mean central subfield thickness change from baseline to W52 was - 24 ± 55 (T&E) and - 33 ± 47 (fixed dosing) μm. Last treatment interval to W76 was ≥ 12 weeks for 37.0% of T&E patients. No new safety signals were identified. CONCLUSION: IVT-AFL T&E can achieve similar functional and anatomic outcomes to fixed dosing every 8 weeks over 52 weeks in patients with nAMD who have completed ≥ 1 year of treatment, while reducing treatment burden. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02540954.
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a injekce intravitreální $7 D058449
650    12
$a makulární degenerace $x farmakoterapie $7 D008268
650    12
$a receptory vaskulárního endoteliálního růstového faktoru $x terapeutické užití $7 D040262
650    12
$a rekombinantní fúzní proteiny $x terapeutické užití $7 D011993
650    _2
$a výsledek terapie $7 D016896
650    _2
$a zraková ostrost $7 D014792
650    _2
$a senioři $7 D000368
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a hodnocení ekvivalence $7 D000073843
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Arias Barquet, Lluís $u Department of Ophthalmology, Hospital Universitario de Bellvitge, Barcelona, Spain $u Department of Ophthalmology, University of Barcelona, Barcelona, Spain
700    1_
$a Papp, András $u Department of Ophthalmology, Semmelweis University, Budapest, Hungary
700    1_
$a Kertes, Peter J $u The John and Liz Tory Eye Centre, Sunnybrook Health Sciences Centre, Toronto, ON, Canada $u Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, ON, Canada $1 https://orcid.org/0000000203485096
700    1_
$a Midena, Edoardo $u Department of Ophthalmology, University Hospital, Padua, Italy
700    1_
$a Ernest, Jan $u Axon Clinical Research Center, Prague, Czech Republic
700    1_
$a Silva, Rufino $u Coimbra Institute for Clinical and Biomedical Research Faculty of Medicine (iCBR-FMUC), University of Coimbra, Coimbra, Portugal $u Ophthalmology Department, Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal $u Association for Innovation and Biomedical Research on Light and Image (AIBILI), Coimbra, Portugal $u Clinical Academic Center of Coimbra (CACC), Coimbra, Portugal $1 https://orcid.org/0000000186760833
700    1_
$a Schmelter, Thomas $u Bayer AG, Berlin, Germany $1 https://orcid.org/0000000313583172
700    1_
$a Niesen, Tobias $u Bayer AG, Berlin, Germany
700    1_
$a Leal, Sergio $u Bayer Consumer Care AG, Basel, Switzerland
773    0_
$w MED00179771 $t Advances in therapy $x 1865-8652 $g Roč. 41, č. 3 (2024), s. 1010-1024
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38183525 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155558 $b ABA008
999    __
$a ok $b bmc $g 2081104 $s 1216695
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 41 $c 3 $d 1010-1024 $e 20240106 $i 1865-8652 $m Advances in therapy $n Adv Ther $x MED00179771
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace